Cybrexa Therapeutics is developing a novel class of peptide-drug conjugates (PDCs) utilizing its proprietary alphalex™ technology to deliver potent anti-cancer agents directly into tumor cells, bypassing the need for antigen targeting. This approach addresses the challenge of effectively treating various solid tumors, including those resistant to conventional therapies, by enhancing drug delivery while minimizing toxicity to healthy tissues.
Funding
$47M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors are resistant to conventional therapies, and effectively delivering anti-cancer agents directly into tumor cells while minimizing toxicity to healthy tissues remains a significant challenge. Current approaches often rely on antigen targeting, which may not be effective for all tumors.
Solution
Cybrexa Therapeutics is developing a novel class of peptide-drug conjugates (PDCs) that utilize its proprietary alphalex™ technology to deliver potent anti-cancer agents directly into tumor cells, independent of surface antigens. The alphalex™ platform employs a pH-low insertion peptide (pHLIP) that targets the acidic environment of tumors, enabling selective drug delivery into the cytoplasm of cancer cells. This approach enhances the efficacy of anti-cancer treatments while reducing off-target effects and toxicity to healthy tissues. Cybrexa's lead candidate, CBX-12, is a first-in-class PDC that utilizes the alphalex™ technology to deliver exatecan, a topoisomerase 1 inhibitor, directly to tumor cells. CBX-12 has demonstrated promising activity across a range of advanced or metastatic solid tumors in Phase 1 clinical trials and is currently in Phase 2 trials for platinum-resistant ovarian cancer.
Target Audience
The primary target audience includes patients with solid tumors, including those resistant to conventional therapies, and oncologists seeking more effective and less toxic treatment options.
Features
- alphalex™ technology platform enables antigen-independent targeting of tumors and metastases with deep tissue penetration.
- pH-Low Insertion Peptide (pHLIP) selectively delivers payloads into the cytoplasm of cancer cells by targeting the acidic tumor microenvironment.
- CBX-12, a first-in-class peptide-drug conjugate (PDC) that delivers exatecan, a potent topoisomerase 1 inhibitor, directly to tumor cells.
- Demonstrated activity across multiple solid tumor types, including ovarian, breast, non-small cell lung cancer (NSCLC), thymic, gallbladder, and colorectal cancers, in Phase 1 clinical trials.
- Manageable safety profile with minimal GI toxicity and no reported cases of interstitial lung disease or ophthalmic toxicity.
- CBX-15 is being developed for solid tumors using MMAE (monomethyl auristatin E) as its payload and is expected to enter the clinic in 2025.